10x Genomics Holds Annual Meeting, Votes on Directors and Auditors

TL;DR

10x Genomics shareholders voted on directors and auditors at their June 11th annual meeting.

AI Summary

On June 11, 2024, 10x Genomics, Inc. filed an 8-K report to announce the results of its 2024 Annual Meeting of Stockholders, which took place on June 11, 2024. The company's stockholders voted on several proposals, including the election of directors and the ratification of the appointment of its independent registered public accounting firm.

Why It Matters

This filing provides transparency on key corporate governance decisions made by 10x Genomics' shareholders, impacting the company's leadership and financial oversight.

Risk Assessment

Risk Level: low — This is a routine corporate filing detailing the outcomes of a shareholder meeting, with no immediate financial or operational risks indicated.

Key Players & Entities

• 10x Genomics, Inc. (company) — Registrant
• June 11, 2024 (date) — Date of earliest event reported
• 2024 Annual Meeting of Stockholders (event) — Subject of the 8-K filing

FAQ

Key Financial Figures

• $0.00001 — tered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market

Filing Documents

• txg-20240611.htm (8-K) — 42KB
• txg-20240611_g1.jpg (GRAPHIC) — 223KB
• 0001770787-24-000040.txt ( ) — 677KB
• txg-20240611.xsd (EX-101.SCH) — 2KB
• txg-20240611_lab.xml (EX-101.LAB) — 21KB
• txg-20240611_pre.xml (EX-101.PRE) — 12KB
• txg-20240611_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders The annual meeting of stockholders of 10x Genomics, Inc. (the "Company") was held on June 11, 2024, via live webcast (the "Annual Meeting"). At the Annual Meeting, there were present, virtually or by proxy, holders of 112,157,824 shares of the Company's Class A and Class B common stock, representing 229,232,830, or approximately 93.10%, of the 246,219,923 eligible votes, constituting a quorum. The matters submitted to a vote at the Annual Meeting and the final voting results of such matters were as follows: Proposal 1 - Election of Directors The Company's stockholders approved the election of one Class II director to hold office for a three-year term expiring at the Company's 2027 annual meeting of stockholders or until her respective successor has been duly elected and qualified or until her earlier resignation or removal. The final voting results were as follows: Nominee Votes For Votes Against Abstentions Broker Non-Votes Kimberly J. Popovits 198,553,136 18,689,301 125,755 11,864,638 Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024. There were no broker non-votes on this proposal. The final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 228,845,897 174,119 212,814 — Proposal 3 - Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval The Company's stockholders did not approve a proposed amendment to the Company's amended and restated bylaws to permit the Company's Board of Directors to amend the Company's amended and restated bylaws without requiring stockholder approval. The final vo

Signatures

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 10x Genomics, Inc. By: /s/ Eric S. Whitaker Name: Eric S. Whitaker Title: Chief Legal Officer Date: June 13, 2024

View Full Filing

View this 8-K filing on SEC EDGAR